Who’s afraid of the Big Bad Breath.12 Feb 2024 18:24
RNS 13th Dec 2023 just 8 weeks ago.
The data confirm the pre|CISIONTM platform's ability to transform the safety profile of doxorubicin through tumour targeting
1. The pre|CISIONTM platform targets the release of a chemotherapy to the tumour as intended.
2. AVA6000 has significantly improved the safety and tolerability of doxorubicin.
3. AVA6000 has shown encouraging preliminary clinical signs of anti-tumour activity.
4. The next steps with AVA6000 involve optimising the patient population, dose and schedule in order to increase efficacy and tolerability of doxorubicin treatment via pre|CISIONTM targeting.
Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:
"Targeting potent therapies to the tumour, while limiting the systemic toxicity that often characterises these therapies, is one of the holy grails of cancer drug development. The data we released today show that the pre|CISION? modification is cleaved specifically by FAP, and not by other human enzymes, and this mechanism can be used to target the activation of a chemotherapy to the tumour microenvironment, significantly reducing the systemic exposure and improving the safety of the drug.
Dr William Tap, Chief, Sarcoma Medical Oncology at Memorial Sloan Kettering Cancer Center, NY also commented:
"These initial clinical data are encouraging and demonstrate that the novel drug delivery mechanism of AVA6000 has the potential to demonstrate single agent activity in patients with solid tumours that express high levels of FAP. The safety data when compared with standard doxorubicin are highly encouraging and demonstrate the power of the pre|CISION? platform to avoid normal tissue effects while concentrating the toxin in the tumor microenvironment."
Well if you want sell your shares because a failed petty journalist who employs trolls on here and “X” to scaremonger and you believe his lies then Sell.
But read again paragraphs above from RNS in December.
Investing is all about research and then holding for gains.
GLA
Sign In
Follow the stocks
